Overview
MNKD market data
Price History
MNKD price chart
Valuation & Profitability
- P/E (TTM)
- 210.05 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -10.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.23 – $6.51 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.2B · P/B 4.03 · P/S 3.13.
Company News
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13Benzinga · Aug 6, 2026, 5:17 PM
MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M EstimateBenzinga · Aug 5, 2026, 8:02 PM
Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14Benzinga · Jul 30, 2026, 2:10 PM
MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary FibrosisBenzinga · Jul 29, 2026, 10:34 AM
8-K filing — MANNKIND CORP (MNKD)SEC EDGAR · Jul 24, 2026, 8:01 PM
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney DiseaseBenzinga · Jul 24, 2026, 6:06 PM
MannKind shares are trading higher after the company announced it received FDA approval of its Furoscix ReadyFlow. Also, the company announced a $50 million private placement financing.Benzinga · Jul 24, 2026, 4:07 PM
MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24Benzinga · Jul 24, 2026, 10:37 AM
MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney DiseaseBenzinga · Jul 24, 2026, 10:33 AM
MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric PatientsBenzinga · Jun 23, 2026, 1:10 PM